Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [839]

The impact of SEABCS 2023

Dr Heather White - Executive Director, TogetHER for Health

The impact of SEABCS 2023 ( Dr Heather White - Executive Director, TogetHER for Health )

OncoAlert Round Up for August 18th - 24th, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 18th - 24th, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

AOH1996 treatment targeting PCNA shows promise for reoccurring solid tumours

Dr Linda Malkas - City of Hope, Duarte, USA

AOH1996 treatment targeting PCNA shows promise for reoccurring solid tumours ( Dr Linda Malkas - City of Hope, Duarte, USA )

Potential benefit to response rates from trastuzumab added to perioperative...

Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of...

Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC ( Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force )

Lenvatinib plus pembrolizumab versus standard of care for previously treated...

Dr Akihito Kawazoe - National Cancer Center Hospital East, Kashiwa, Japan

Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer ( Dr Akihito Kawazoe - National Cancer Center Hospital East, Kashiwa, Japan )

Whole exome sequencing reveals genomic landscape of appendiceal adenocarcinoma

Dr Michael White - MD Anderson Cancer Center, Houston, USA

Whole exome sequencing reveals genomic landscape of appendiceal adenocarcinoma ( Dr Michael White - MD Anderson Cancer Center, Houston, USA )

Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma

Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain

Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma ( Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain )

ADCLEC.syn1 and CD33-CARS in humanised acute myeloid leukaemia models shows...

Dr Sascha Haubner - Memorial Sloan Kettering Cancer Center, New York City, USA

ADCLEC.syn1 and CD33-CARS in humanised acute myeloid leukaemia models shows promising efficacy ( Dr Sascha Haubner - Memorial Sloan Kettering Cancer Center, New York City, USA )

Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard...

Dr Krina Patel - MD Anderson Cancer Center, Houston, USA

Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens ( Dr Krina Patel - MD Anderson Cancer Center, Houston, USA )

A randomised trial of the FLT3 inhibitor gilteritinib as post-transplant...

Dr Mark Levis - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center...

A randomised trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML ( Dr Mark Levis - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic...

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City...

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )

Advancing breast cancer treatment in Uganda by improving molecular testing

Dr Jackson Orem - Uganda Cancer Institute, Kampala, Uganda

Advancing breast cancer treatment in Uganda by improving molecular testing ( Dr Jackson Orem - Uganda Cancer Institute, Kampala, Uganda )

More from ecancer